CJC-1295
Synthetic analog of growth hormone-releasing hormone (GHRH) with an extended half-life. Frequently combined with ipamorelin to potentiate GH release. Available in versions with and without DAC (Drug Affinity Complex).
Last updated:: 06/04/2026
Research Status
ANVISA (Brazil)
Not regulated
FDA (USA)
Compounding only
EMA (Europe)
Not regulated
Mechanism of Action
CJC-1295 mimics natural GHRH, binding to receptors in the anterior pituitary to stimulate growth hormone synthesis and release. The DAC version binds to serum albumin, extending the half-life from minutes to days. It amplifies the natural GH pulses without suppressing the hypothalamic-pituitary axis.
Study Protocols
Dosages and regimens used in published clinical studies. This does not constitute a medical prescription.
Estímulo de GH / antienvelhecimento
Subcutânea (SC)Pico rápido, melhor antes de dormir
Com DAC (Drug Affinity Complex): meia-vida de ~8 dias. Sem DAC: meia-vida ~30 min, requer múltiplas aplicações.
Benefits
Sustained increase in GH and IGF-1
ProvenA human study demonstrated a 2-10x increase in GH levels and a 1.5-3x increase in IGF-1 levels after a single dose.
View studyRisks and Side Effects
Injection site reaction
Low(Common)Redness, swelling, or pain at the subcutaneous injection site.
Water retention
Low(Variable)Mild edema may occur, related to increased GH/IGF-1 levels.
Studies and References (1)
Teichman SL, Neale A, Lawrence B, et al. — Journal of Clinical Endocrinology & Metabolism (2006) — n=33
Dose única de CJC-1295 resultou em aumento sustentado de GH por até 6 dias e aumento de IGF-1 por até 14 dias em adultos saudáveis.
PubMedImportant notice
This content is strictly informational and educational, based on published scientific research. It does not constitute medical advice, prescription, or encouragement to use any substance. Always consult a qualified physician before starting any treatment.
How to Obtain
This compound can be prepared by licensed compounding pharmacies with a valid prescription. Consult a physician first.